Eyenovia to Report Third Quarter 2020 Results on Tuesday, November 10
Eyenovia, Inc. (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company, will announce its Q3 2020 financial results on November 10, 2020, after market close. This will be followed by a conference call at 4:30 PM ET, featuring CEO Dr. Sean Ianchulev, CFO John Gandolfo, and VP Michael Rowe. Interested parties can join by calling 877-407-9039 or 201-689-8470 (international) with conference code 13713084. A webcast will also be accessible on the investor relations page of Eyenovia's website, where the event will be archived for one year.
- None.
- None.
Company to host an investor conference call and webcast at 4:30pm ET on that day
NEW YORK, Nov. 05, 2020 (GLOBE NEWSWIRE) -- Eyenovia, Inc., (NASDAQ: EYEN), a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics, today announced that the Company will release financial results for the third quarter ended September 30, 2020 on Tuesday, November 10, 2020, after market close. Following the release, Eyenovia’s Chief Executive Officer and Chief Medical Officer Dr. Sean Ianchulev, Chief Financial Officer John Gandolfo, and Vice President of Commercial Michael Rowe, will host a conference call to review the financial and operating results.
The conference call is scheduled to begin at 4:30 pm ET on Tuesday, November 10, 2020. Participants should dial 877-407-9039 (domestic) or 201-689-8470 (international) with the conference code 13713084. A live webcast of the conference call will also be available on the investor relations page of the Company's corporate website at www.eyenovia.com.
After the live webcast, the event will be archived on Eyenovia’s website for one year.
About Eyenovia, Inc.
Eyenovia, Inc. (NASDAQ: EYEN) is a clinical stage ophthalmic biopharmaceutical company developing a pipeline of microdose array print (MAP™) therapeutics. Eyenovia’s pipeline is currently focused on the late-stage development of microdosed medications for presbyopia, pediatric myopia progression and mydriasis. For more Information, please visit www.eyenovia.com.
Eyenovia Investor Contacts:
John Gandolfo
jgandolfo@eyenovia.com
(917) 289-1117
Eric Ribner
LifeSci Advisors, LLC
eric@lifesciadvisors.com
(646) 751-4363
Eyenovia Media Contact:
Diana Soltesz
Pazanga Health Communications
dsoltesz@pazangahealth.com
(818) 618-5634
FAQ
When will Eyenovia release its Q3 2020 financial results?
What time is Eyenovia's investor conference call on November 10, 2020?
Who will present during Eyenovia's conference call?
How can I access Eyenovia's conference call?